Efficacy And Safety Of Lenalidomide In The Treatment Of A Refractory Multicentric Castleman Disease Patient

Gaixiang Xu,Liping Mao,Min Yang,Hui Liu,Jie Jin,Wenbin Qian
2016-01-01
Abstract:Castleman's disease (CD) is a lymphoproliferative disorder of unknown etiology characterized by enlarged hyperplastic lymph nodes with marked vascular proliferation. Three histological variants (hyaline vascular, plasma cell, and mixed) and two clinical types (localized and multicentric) have been described. Patients with multicentric Castleman's disease (MCD) have less favorable prognoses and require systemic treatments. The incidence of MCD is low but it has a very high percentage of recurrence despite treatment. Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with multiple myeloma (MM). In recent clinical trials, lenalidomide has shown promising activity in other hematologic malignancies. Herein, we shared our experience on the safety and effectiveness of lenalidomide in the treatment of a 20-year old male patient with refractory plasma cell type MCD. This is a very rare case. As far as we know, the reports related to the use of lenalidomide on CD were limited to Prof Szturz P from Czech. In the report, we alsodo a critical and extensive of the published literature review.
What problem does this paper attempt to address?